Company intelligence / Profile preview

Inves Biofarm

Granada, Andalusia, Spain

Ownership: Private
Employees: ~20
Development stage: Other

Overview

Inves Biofarm is focused on the research, development, and manufacturing of orphan drugs and biotechnological health products. Key recent results include the successful clinical investigation of an emulgel containing recombinant human epidermal growth factor (sh-Oligopeptide-1) and polyphenols for the treatment of atopic dermatitis, showing significant improvements in skin hydration and barrier function.

Therapeutic areas: RheumatologyRare DiseasesWomen's HealthDermatology
Modalities: PeptidesSmall moleculeRecombinant proteinBiologicMedical device
Industry: Biotech

Drug pipeline

1 asset

emulgel

Preclinical

Partnerships

Universidad de GranadaHospital Universitario Virgen de las NievesHospital Universitario Clínico San CecilioLeitat Technological CenterVall d'Hebron Hospital

Beyond the preview

Go deeper on Inves Biofarm.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Inves Biofarm.

Explore the full profile